Euronext has launched the Euronext Equileap Gender Equality Eurozone 1001 and Euronext Equileap Gender Equality France 402 indices. These gender equality indices are the first pillars of a broader family of indices addressing challenges around gender balance in the workplace.
In response to the UN’s Sustainable Development Goal (SDG) #5 “Gender Equality”, these indices have been developed by Euronext leveraging on Equileap’s Scorecard and Alarm Bell list to help market participants invest in listed companies committed to improving gender diversity and to respond to the increasing demand for Social thematic investments. The index methodology also applies activity-based exclusions, UNGC compliance and controversial activities exclusion.
The companies included in the indices are selected based on their gender equality score across four different categories: gender balance in leadership and workforce; equal compensation and work-life balance; policies promoting gender equality
commitment, transparency and accountability.
The gender equality score provider for these indices, Equileap, assesses each company’s commitment to gender equality from its boardroom to its supply chain, and is inspired by the UN Women’s Empowerment principles. Euronext is one of the leading ESG index providers in Europe. Since 2021, Euronext has launched over 30 new ESG indices covering new categories to invest in, including broad ESG considerations, specific themes such as PAB, CTB, Biodiversity, Hydrogen, Water and Social as well as launching ESG versions of our national benchmark indices, the AEX ESG in Amsterdam and the OBX ESG in Oslo, following the successful launch of the MIB ESG in Milan and the CAC 40 ESG in Paris.
As an official partner of the Sustainable Stock Exchanges Initiative, Euronext firmly commits to the UN’s “2030 Agenda for Sustainable Development” and thereby to the 17 Sustainable Development Goals (SDGs). Euronext has selected the SDGs that are most relevant to its impact areas, including SDG 5 Gender Equality, in its strategy.